Anavex Life Sciences Corp (AVXL)

[frrol]

Anavex is hypothesizing that these CNS indications can in many, and perhaps even most, patient cases share some fundamental common causes or factors, and that using intense data analysis with AI tools they can be elucidated and patients can then be characterized as treatment 'groups'. The hope for us is that we can then figure out who would be helped with our S1 agonists, and to what extent. Such predictive ability would be valuable for future trials, and then commercially. These AI efforts are the "sizzle" of our trials. The "steak" of course is the efficacy results. (Sizzle is irrelevant for gristle.)